These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. Del Poeta G; Bomben R; Polesel J; Rossi FM; Pozzo F; Zaina E; Cattarossi I; Varaschin P; Nanni P; Boschian Boschin R; Postorino M; Laureana R; Pasqualone G; Steffan A; Gentile M; Zucchetto A; Gattei V Hematol Oncol; 2021 Dec; 39(5):712-714. PubMed ID: 34462939 [No Abstract] [Full Text] [Related]
4. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Parry H; McIlroy G; Bruton R; Ali M; Stephens C; Damery S; Otter A; McSkeane T; Rolfe H; Faustini S; Wall N; Hillmen P; Pratt G; Paneesha S; Zuo J; Richter A; Moss P Blood Cancer J; 2021 Jul; 11(7):136. PubMed ID: 34330895 [TBL] [Abstract][Full Text] [Related]
5. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis. Molica S; Giannarelli D; Montserrat E Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031 [No Abstract] [Full Text] [Related]
6. Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Sällberg Chen M; Zain R; Hansson L; Österborg A Leukemia; 2022 Feb; 36(2):476-481. PubMed ID: 34564699 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Herishanu Y; Rahav G; Levi S; Braester A; Itchaki G; Bairey O; Dally N; Shvidel L; Ziv-Baran T; Polliack A; Tadmor T; Benjamini O; Blood; 2022 Feb; 139(5):678-685. PubMed ID: 34861036 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Monin L; Laing AG; Muñoz-Ruiz M; McKenzie DR; Del Molino Del Barrio I; Alaguthurai T; Domingo-Vila C; Hayday TS; Graham C; Seow J; Abdul-Jawad S; Kamdar S; Harvey-Jones E; Graham R; Cooper J; Khan M; Vidler J; Kakkassery H; Sinha S; Davis R; Dupont L; Francos Quijorna I; O'Brien-Gore C; Lee PL; Eum J; Conde Poole M; Joseph M; Davies D; Wu Y; Swampillai A; North BV; Montes A; Harries M; Rigg A; Spicer J; Malim MH; Fields P; Patten P; Di Rosa F; Papa S; Tree T; Doores KJ; Hayday AC; Irshad S Lancet Oncol; 2021 Jun; 22(6):765-778. PubMed ID: 33930323 [TBL] [Abstract][Full Text] [Related]
9. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. Benda M; Mutschlechner B; Ulmer H; Grabher C; Severgnini L; Volgger A; Reimann P; Lang T; Atzl M; Huynh M; Gasser K; Petrausch U; Fraunberger P; Hartmann B; Winder T Br J Haematol; 2021 Nov; 195(4):523-531. PubMed ID: 34346068 [TBL] [Abstract][Full Text] [Related]
10. Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Parry H; McIlroy G; Bruton R; Damery S; Tyson G; Logan N; Davis C; Willett B; Zuo J; Ali M; Kaur M; Stephens C; Brant D; Otter A; McSkeane T; Rolfe H; Faustini S; Richter A; Lee S; Wandroo F; Shafeek S; Pratt G; Paneesha S; Moss P J Hematol Oncol; 2022 Jan; 15(1):3. PubMed ID: 35000597 [TBL] [Abstract][Full Text] [Related]
11. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336 [TBL] [Abstract][Full Text] [Related]